Neuroprotection during cardiac surgery: a randomised trial of a platelet activating factor antagonist.

Journal article

OBJECTIVE: To assess platelet activating factor (PAF) antagonists, potent neuroprotective agents in experimental cerebral dysfunction, in clinical practice. DESIGN: Double blind, minimised, placebo controlled trial of low and high dose PAF antagonist (lexipafant). SETTING: Cardiac surgery unit. PATIENTS: 150 patients undergoing coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass. INTERVENTIONS: Randomisation to placebo, low dose (10 mg) or high dose (100 mg) lexipafant. ...

Expand abstract

Authors: Taggart, D; Browne, S; Wade, D; Halligan, P

• Publication status: Published
• Journal: Heart (British Cardiac Society)
• Volume: 89
• Issue: 8
• Pages: 897-900
• Publication date: 2003-08-01
• DOI: 10.1136/heart.89.8.897
• EISSN: 1468-201X
• ISSN: 1355-6037
• Language: English
• Keywords: Female; Double-Blind Method; Platelet Activating Factor; Neuroprotective Agents; Cognition Disorders; Imidazoles; Neuropsychological Tests; Middle Aged; Male; Humans; Leucine; Coronary Artery Bypass